RT Journal Article
SR Electronic
T1 Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <em>KRAS-</em>mutated non-small cell lung cancer with <em>STK11</em>, <em>KEAP1,</em> or <em>TP53</em> comutations: subgroup results from the phase III IMpower150 trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e003027
DO 10.1136/jitc-2021-003027
VO 10
IS 2
A1 West, Howard Jack
A1 McCleland, Mark
A1 Cappuzzo, Federico
A1 Reck, Martin
A1 Mok, Tony SK
A1 Jotte, Robert M
A1 Nishio, Makoto
A1 Kim, Eugene
A1 Morris, Stefanie
A1 Zou, Wei
A1 Shames, David
A1 Das Thakur, Meghna
A1 Shankar, Geetha
A1 Socinski, Mark A
YR 2022
UL http://jitc.bmj.com/content/10/2/e003027.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.